5-HT2 receptor antagonism reduces human motoneuron output to antidromic activation but not to stimulation of corticospinal axons

Jacob R. Thorstensen1 | Janet L. Taylor2,3 | Justin J. Kavanagh1

1Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland, Australia
2School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia
3Neuroscience Research Australia, Sydney, New South Wales, Australia

Abstract

The intrinsic electrical properties of motoneurons strongly affect motoneuron excitability to fast-acting excitatory ionotropic inputs. Serotonin (5-HT) is a neurochemical that alters the intrinsic properties of motoneurons, whereby animal models and in vitro experiments indicate that 5-HT increases motoneuron excitability by activating 5-HT2 receptors on the somato-dendritic compartment. In the current study, we examined how antagonism of the 5-HT2 receptor affects motoneuron excitability in humans. We hypothesised that motoneuron excitability would be reduced. The 5-HT2 antagonist cyproheptadine was administered to 10 healthy participants in a double-blinded, placebo-controlled, crossover trial. Electrical cervicomedullary stimulation was used to deliver a synchronised excitatory volley to motoneurons to elicit cervicomedullary motor evoked potentials (CMEPs) in the surface electromyography (EMG) signal of the resting biceps brachii. Likewise, electrical peripheral nerve stimulation was used to generate antidromic spikes in motoneurons and cause recurrent discharges, which were recorded with surface EMG as F-waves in a resting hand muscle. Compared with placebo, we found that 5-HT2 antagonism reduced the amplitude and persistence of F-waves but did not affect CMEP amplitude. 5-HT2 antagonism also reduced maximal contraction strength. The reduced recurrent discharge of motoneurons with 5-HT2 antagonism suggests that 5-HT2 receptors modulate the electrical properties of the initial segment or soma to promote excitability. Conversely, as cyproheptadine did not affect motoneuron excitability to brief synaptic input, but affected maximal contractions requiring sustained input, it seems likely that the 5-HT2-mediated amplification...
of synaptic input at motoneuron dendrites is functionally significant only when excitatory input activates persistent inward currents.

**KEYWORDS**
cervicomедullary motor evoked potential, F-wave, ionotropic, neuromodulation, raphe nuclei, serotonin

## 1 INTRODUCTION

The intrinsic electrical properties of motoneurons markedly influence the magnitude of excitatory post-synaptic potentials (EPSPs) arising from fast-acting excitatory ionotropic inputs (Heckman & Enoka, 2012). Motoneuronal properties are heavily affected by the release of neuromodulators arising from descending brainstem projections (Heckman et al., 2009; Heckman & Enoka, 2012; Rekling et al., 2000). Serotonin (5-HT) is an example of a neuromodulator that has strong effects on motoneuron excitability (i.e., the output of motoneurons to excitatory input). The release of central nervous system (CNS) 5-HT is predominantly controlled by the brainstem raphe nuclei (Hornung, 2003), but there are also intraspinal 5-HT producing neurons (Zhang, 2015). Descending raphe projections form direct monosynaptic connections with the dendrites and soma of motoneurons (Alvarez et al., 1998; Pilowsky et al., 1990; Ridet et al., 1994). At motoneurons, 5-HT enhances the efficacy of ionotropic inputs through the activation of metabotropic receptors coupled to G-proteins (Heckman et al., 2009; Perrier et al., 2013). Specifically, metabotropic 5-HT receptors modulate the electrical properties of motoneurons to promote recruitment and discharge, so that motoneurons are brought above their threshold for discharge, and discharge more frequently, with smaller magnitudes of ionotropic input (Perrier et al., 2013).

Experiments performed in adult turtle spinal cord slice preparations demonstrate that 5-HT increases motoneuron excitability by activating 5-HT2 receptors on the somatodendritic compartment (Hsiao et al., 1997; Perrier & Hounsgaard, 2003). The facilitatory effects of 5-HT2 receptor activation on dendritic persistent inward currents (PICs) are especially strong (Harvey et al., 2006a, 2006b; Murray, Stephens, Ballou, et al., 2011; Perrier & Delgado-Lezama, 2005; Perrier & Hounsgaard, 2003). PICs amplify ionotropic input significantly and promote the sustained discharge of motoneurons, and the amplitude of PICs appear to correspond closely to the amount of 5-HT available to activate 5-HT2 receptors on motoneurons (Heckman et al., 2003, 2009; Heckman, Hyngstrom, & Johnson, 2008). It is important to highlight that a sustained depolarizing current is usually needed to activate PICs (Heckman, Johnson, et al., 2008). In voluntary contractions, this comprises sustained ionotropic input from the corticospinal system, and other descending and sensory afferent pathways, that slowly brings motoneurons above their threshold for discharge. In this regard, 5-HT puts PICs in a facilitated state but does not cause motoneuronal activation, and 5-HT-mediated increases in motoneuron excitability are strongest when PICs are activated by excitatory input (Heckman et al., 2009).

In addition to facilitatory effects on PICs, which are activated by sustained excitatory input and enhance motoneuron output, 5-HT2 receptors also modulate the resting membrane potential of motoneurons to increase excitability (Perrier et al., 2013; Perrier & Cotel, 2015). Specifically, 5-HT2 receptors inhibit leak potassium channels and facilitate a hyperpolarization activated inward current (Hsiao et al., 1997). Together, these actions depolarize the resting membrane potential of motoneurons to lower the magnitude of ionotropic input needed for recruitment. If 5-HT increases the excitability of motoneurons in slice preparations and animal models, 5-HT could also increase the in vivo excitability of motoneurons in human participants. In support of this proposition, studies using drug interventions indicate that 5-HT2 receptors are particularly important and indeed act to increase human motoneuron excitability. For example, 5-HT2 antagonists reduce spasticity after spinal cord injury by blocking constitutive 5-HT2 receptor activity at motoneurons (D’Amico, Murray, et al., 2013; Murray et al., 2010). Likewise, in neurologically healthy individuals, 5-HT2 antagonism decreases estimates of PIC amplitude (D’Amico, Murray, et al., 2013) and reduces force variability (Wei et al., 2014). However, motor cortical stimulation and voluntary contractions first activate sites upstream of motoneurons (that are also affected by 5-HT active drugs), so it is not known if/how 5-HT2 antagonism affects human motoneuron excitability directly.

The purpose of this study was to examine if antagonism of the 5-HT2 receptor affects human motoneuron excitability. Under conditions of 5-HT2 antagonism, submaximal stimulation of corticospinal axons at the level of
the cervicomedullary junction was used to deliver a synchronised excitatory volley to motoneurons and evoke cervicomedullary motor evoked potentials (CMEPs) in the resting biceps brachii. Cervicomedullary stimulation rapidly brings motoneurons above their threshold for discharge and causes motoneurons to discharge only once (Berardelli et al., 1991), such that CMEPs are unlikely to reflect the 5-HT₂ receptor modulation of PICs. We also used supramaximal stimulation of motoneuron axons to generate antidromic spikes and cause the recurrent discharge of motoneurons, which were recorded as F-waves in a resting hand muscle. F-waves do not reflect the synaptic activation of motoneurons and are probably sensitive to the excitability of the axon initial segment and soma (McNeil et al., 2013). Compared with placebo, we hypothesised that both the synaptic and antidromic activation of motoneurons would generate muscle responses that were smaller in amplitude and less persistent for F-waves, after administration of a 5-HT₂ antagonist.

As serotonergic projections to the spinal cord are diffuse (Bowker et al., 1982; Heckman, Hyngstrom, & Johnson, 2008; Holstege & Kuypers, 1987) and voluntary motor activity causes 5-HT release to the spinal cord (Jacobs et al., 2002; Veasey et al., 1995; Wei et al., 2014), we also examined CMEPs after a strong contraction of the contralateral limb and hypothesised that 5-HT₂ receptor antagonism would lead to greater reductions in motoneuron excitability at this time because of the stronger influence of 5-HT. Maximal contraction performance was also assessed to determine if 5-HT₂ receptor antagonism affected voluntary motor output. Overall, we found that F-waves but not CMEPs were reduced by 5-HT₂ antagonism, thus indicating that 5-HT₂ antagonism reduces motoneuronal recurrent discharge but not excitability to brief synaptic input. We also found that 5-HT₂ antagonism reduced maximal contraction strength, which suggests that the 5-HT-mediated amplification of synaptic input at motoneurons is strong only when motoneurons fire repetitively and dendritic PICs are activated.

2 | MATERIALS AND METHODS

2.1 | Experimental design

This study was a human, double-blind, placebo-controlled, counterbalanced crossover study. Participants attended the laboratory on two occasions separated by a minimum of 1 week. At one testing session, cyproheptadine was administered to examine how 5-HT₂ antagonism affects the excitability of motoneurons projecting to resting muscle. Measures of motoneuron excitability were obtained before (baseline) and after (post-pill) placebo and drug administration during the two testing days.

2.2 | Ethical approval

Ethical approval was obtained via the Human Research Ethics committee at Griffith University (Griffith University Reference Number: 2019/339), and written informed consent was obtained prior to testing. All testing procedures were performed in accordance with the Declaration of Helsinki.

2.3 | Participants

Twelve healthy participants were initially recruited for this study. Participants were screened using a medical history questionnaire which contained exclusion criteria specific to nervous system and upper-limb musculoskeletal injury, cyproheptadine administration and electrical stimulation. Recruited participants also attended a familiarisation session, where we ensured that participants could tolerate cervicomedullary stimulation and that biceps brachii responses to cervicomedullary stimulation were free of early latency components. An early onset latency of an evoked potential from cervicomedullary stimulation signifies the direct stimulation of cervical nerve roots (see Section 2.6). During familiarisation, three participants displayed early latency components to cervicomedullary stimulation and were excluded from testing because of this. The remaining nine participants completed both the cervicomedullary stimulation and F-wave components of the study, and one excluded participant opted to complete the F-wave component only (n = 10 were administered drug, participant age: 26.3 ± 4.1 years old, three female). Participants were asked to refrain from any stimulants or depressants such as caffeine, alcohol or exercise on the morning of testing until testing had finished for the day.

2.4 | Drug intervention

A single 8-mg oral dose of the 5-HT₂ receptor antagonist cyproheptadine, or a placebo, was administered to participants immediately after baseline measurements were obtained. Post-pill testing commenced after 3 h had passed from pill administration. The drug and placebo capsules were similar in appearance, where the placebo contained non-active excipients frequently used in drug compounding. Although also an antihistamine, cyproheptadine has strong antiserotonin effects. In human
neurophysiology experiments, a standardised 8-mg dose of cyproheptadine has been used to attenuate the post-synaptic effects of the 5-HT$_2$ receptor at motoneurons (D’Amico, Murray, et al., 2013; Murray et al., 2010; Seo et al., 2011; Thorstensen et al., 2021; Wei et al., 2014).

2.5 Participant setup and EMG

Participants sat upright in a chair with both arms by their side. Both elbows were positioned in ~90° of flexion, and the right wrist was supinated with the palm upwards. The right arm for each participant was firmly strapped to an armrest at the elbow, wrist and fingers to prevent changes in upper-limb position during testing. Surface electromyography (EMG) signals were obtained from the right biceps brachii and abductor digiti minimi (ADM) via Ag/AgCl electrodes (Kendall ARBO, 24 mm diameter). A belly-tendon arrangement was employed for both the biceps brachii and ADM. All biceps brachii and ADM EMG were amplified ($\times$100 or 300) and bandpass filtered between 10 and 1000 Hz (CED 1902, Cambridge Electronic Design Ltd., UK), and sampled at 5000 Hz using a Power 1401 data acquisition interface with Signal software (version 6, Cambridge Electronic Design Ltd., UK). For the ADM, an additional channel was used to collect EMG for F-wave analysis. This channel was highly amplified ($\times$1000) and highly filtered (bandpass between 200 and 1000 Hz) to reduce the duration of the M-wave tail such that it was easier to identify F-waves (D’Amico et al., 2017; Khan et al., 2012, 2016).

2.6 Cervicomedullary stimulation

Electrical stimuli were applied to corticospinal axons at the level of the cervicomedullary junction to elicit CMEPs in the resting biceps brachii. This muscle was chosen as the threshold for eliciting resting biceps CMEPs is typically lower compared with distal muscles of the upper limb, thus minimising participant discomfort associated with higher intensity cervicomedullary stimulation. A constant current stimulator (DS7AH, Digitimer Ltd., UK) was used to deliver stimuli with a pulse width of .2 ms to generate the antidromic wave in the ulnar nerve. A surface cathode and anode were positioned ~2 cm apart, where the anode was positioned distal to the cathode and ~2–3 cm proximal to the wrist joint. All ulnar nerve stimuli were supramaximal (150% of the current used to obtain a maximal ADM $M_{\text{max}}$, range: 45–105 mA). This supramaximal intensity was determined prior to pill ingestion and remained fixed within each testing session. There was a 2-s interval (.5-Hz stimulation frequency) between each ulnar nerve stimulation.

2.7 Brachial plexus stimulation

Electrical stimuli were applied to axons of biceps brachii motoneurons at the brachial plexus to generate a biceps $M_{\text{max}}$. A constant current stimulator (DS7AH, Digitimer Ltd., UK) with a pulse width of .2 ms was used to deliver stimulation. A surface cathode was positioned overlying the supraclavicular fossa at Erb’s point, and a surface anode was positioned on the acromion. For the placebo and cyproheptadine sessions, stimulator intensity was set at 130% of the current used to obtain a maximal evoked biceps brachii EMG response before pill ingestion (range: 52–156 mA). Once this stimulator intensity was determined, it remained fixed throughout the testing session.

2.8 Ulnar nerve stimulation

Because the appearance of F-waves in the biceps brachii EMG signal can be masked by the tail of the preceding M-wave, we selected a distal upper-limb muscle to record F-waves with a longer onset latency. Hence, electrical stimuli were applied to the ulnar nerve at the wrist to generate F-waves in the ADM. A constant current stimulator (DS7AH, Digitimer Ltd., UK) with a pulse width of .2 ms was used to generate the antidromic wave in the ulnar nerve. A surface cathode and anode were positioned ~2 cm apart, where the anode was positioned distal to the cathode and ~2–3 cm proximal to the wrist joint. All ulnar nerve stimuli were supramaximal (150% of the current used to obtain a resting ADM $M_{\text{max}}$, range: 45–105 mA). This supramaximal intensity was determined prior to pill ingestion and remained fixed within each testing session. There was a 2-s interval (.5-Hz stimulation frequency) between each ulnar nerve stimulation.
Experiment protocol

After the participant was prepared for testing, and relevant stimulation intensities were determined, three blocks of baseline stimulations were completed (Figure 1). Within each block, five cervicomedullary stimuli were used to obtain CMEPs and three brachial plexus stimuli were used to obtain $M_{max}$ for the biceps brachii. There were 10-s inter-stimulus intervals between all cervicomedullary and brachial plexus stimuli. Each block also contained 60 ulnar nerve stimuli. Following baseline measurements, participants ingested a placebo or cyproheptadine. Three hours after pill administration, a further five stimulation blocks were obtained to assess post-pill changes in evoked responses. All stimulation blocks were separated by 5 min. Before baseline and post-pill testing, we ensured participants were in a comfortable position before measurements were obtained, and we asked participants to rest with no movement for ~5 min to ensure they were relaxed before stimulations were delivered. Throughout testing, participants were instructed to minimise voluntary movement, and EMG was monitored during stimulation blocks to ensure muscles were free of voluntary activity.

Additional data were collected to determine if remote contraction of the contralateral limb affected CMEPs under conditions of 5-HT$_2$ antagonism. Voluntary contraction of a remote muscle group, such as the opposite non-test limb, likely promotes diffuse serotonergic drive to the spinal cord, which will affect nearby motoneuron pools innervating contralateral homologous muscles (e.g., the biceps of the test limb) (Wei et al., 2014). All muscle contractions in this experiment were performed at the end of testing on both days so that voluntary activity did not affect baseline and post-pill measures of resting motoneuron excitability. For all contractions, the wrist of the left limb was attached to a calibrated load cell (~1100-N capacity, SM-250 S-type, Interface Inc., USA) via a non-compliant strap. Participants initially performed three brief (~2 to 3 s) maximal voluntary contractions (MVCs) to obtain an estimate of maximal force generating capability for the non-test limb. For MVCs, real-time visual feedback of force and verbal encouragement were provided to ensure each participant was contracting at maximal effort. After peak MVC force was established, participants generated five brief (~4 s) isometric elbow flexions at 75% MVC, where each contraction was followed by cervicomedullary and brachial plexus stimulations approximately 1 and 3 s after contraction. EMG responses to cervicomedullary and brachial plexus stimulation were measured in the relaxed right biceps brachii directly after each contraction. Participants were instructed to immediately relax both limbs after contraction of the left limb so that all stimulations were applied when the right biceps brachii was at rest. Biceps EMG was monitored to ensure the elbow flexors of the test limb were relaxed. All contractions were separated by 2 min to minimise fatigue and standardise rest periods.

**FIGURE 1** Experiment protocol used to assess motoneuron excitability. Participants attended two sessions where a placebo or cyproheptadine was administered. Baseline and post-pill measures were made for cervicomedullary motor evoked potentials (CMEPs, closed arrows) and F-waves (clustered vertical lines). Brachial plexus stimuli were also used to obtain biceps maximal compound muscle action potentials ($M_{max}$ open arrows). Three blocks of baseline stimulations and five blocks of post-pill stimulations were delivered. Each block included 5 biceps CMEPs, 3 biceps $M_{max}$ and 60 stimuli for F-waves. Blocks were separated by 5 min. After resting measurement blocks were completed, brief submaximal elbow flexions (at 75% of maximal voluntary contraction, MVC) were performed with the contralateral limb. Directly after each contraction of the contralateral limb, responses to cervicomedullary and brachial plexus stimulation were recorded (single submaximal contraction and stimulations = 1 block). Five submaximal contraction blocks were completed for post-ingestion conditions separated by 2 min.
2.10 Data analysis

The peak-to-peak amplitudes of CMEPs and $M_{\text{max}}$ were calculated from the biceps EMG signal. Average CMEP amplitudes were first normalised to average $M_{\text{max}}$ amplitudes, and post-pill CMEP amplitudes were normalised to baseline amplitudes to account for between-session differences. The peak-to-peak amplitudes of F-waves were extracted from heavily filtered EMG data and normalised to heavily filtered $M_{\text{max}}$ amplitudes. Average post-pill F-wave amplitudes were then normalised to baseline amplitudes. In addition to amplitude measures, F-wave persistence was calculated by counting the number of times an F-wave was present relative to the number of ulnar nerve stimuli. We deemed an F-wave to be present if there was a clear waveform response with an amplitude $\geq 20 \mu V$ within the 25- to 50-ms time window after stimulation. Baseline F-wave persistence values were subtracted from post-pill persistence values so that a negative value represents a reduction from baseline. All CMEP and F-wave data are presented in figures as either a percentage (%) of baseline or change from baseline. Change scores were also calculated for post-pill measures as a difference from placebo values (cyproheptadine–placebo), and these change scores are also presented in figures. A negative change score denotes a reduction in amplitude or persistence for the cyproheptadine condition relative to placebo. All data were analysed using Signal software (version 6, Cambridge Electronic Design Ltd., UK).

2.11 Statistical analysis

Shapiro–Wilk tests were used to assess normality. To identify differences between drug conditions, two-tailed paired samples $t$ tests were employed for peak MVC force, CMEP amplitude and F-wave amplitude. Data were not normally distributed for F-wave persistence,

![Figure 2](image-url) Changes in biceps brachii cervicomedullary motor evoked potential (CMEP) amplitude after placebo (PLA) and cyproheptadine (CYP) administration. (a) Waveform averages of biceps CMEPs are shown for a single participant before (baseline) and after (post-pill) administration of placebo (top panel) and cyproheptadine (bottom panel). Baseline traces are the average of 15 CMEPs and post-pill traces are the average of 25 CMEPs. Dotted horizontal traces denote the maximum and minimum waveform responses at baseline for each drug condition. (b) Post-pill CMEP amplitudes are shown for the group (mean $\pm SD, n = 9$). Individual values for each participant are also shown. CMEP amplitudes were first normalised to the amplitude of the maximal compound muscle action potential ($M_{\text{max}}$), and then normalised to baseline CMEP (% of $M_{\text{max}}$) values. (c) Individual post-pill CMEP amplitudes are shown for the cyproheptadine condition, where cyproheptadine amplitudes are presented as a difference from post-pill placebo values to show the direction of change for each participant after drug intake (cyproheptadine minus placebo).
Table 1  Biceps brachii and abductor digiti minimi (ADM) maximal compound muscle action potential (Mmax) amplitude values

|                          | Resting muscle |                   |                   |                   |          |                   |          |
|--------------------------|----------------|-------------------|-------------------|-------------------|----------|-------------------|----------|
|                          | Pre-PLA        | Pre-CYP           | Post-PLA          | Post-CYP          |          | Post-PLA          | Post-CYP |
| Biceps brachii (mV)      | 18.3 ± 6.8     | 18.0 ± 8.4        | 19.4 ± 7.4        | 19.6 ± 9.3        |          | 19.2 ± 7.7        | 19.7 ± 9.2 |
| ADM (mV)                 | 17.3 ± 2.4     | 18.0 ± 2.1        | 17.9 ± 2.2        | 17.8 ± 2.3        |          | —                 | —        |

Note: ADM is abductor digiti minimi, PLA is placebo, and CYP is cyproheptadine. ADM M-waves were obtained from wide band pass EMG signals. Data are presented as group means ± SD (n = 9 for biceps brachii and n = 10 for ADM).

Figure 3  Changes in abductor digiti minimi F-wave amplitude and persistence after placebo (PLA) and cyproheptadine (CYP) administration. (a) Individual F-waves are shown for a single participant before (baseline) and after (post-pill) administration of placebo (top panel) and cyproheptadine (bottom panel). Thirty consecutive responses to stimulation are overlaid for each collection of traces. F-waves are shown without the preceding M-wave, and each trace is the time window from 24 to 50 ms after stimulation. (b) Post-pill F-wave amplitudes are shown for the group. Individual values for each participant are also shown. Individual F-wave amplitudes were first normalised to the amplitude of the maximal compound muscle action potential (Mmax), and then normalised to baseline F-wave (% of Mmax) values. (c) Individual post-pill F-wave amplitudes are shown for the cyproheptadine condition, where cyproheptadine amplitudes are presented as a difference from post-pill placebo values to show the direction of change for each participant after drug intake (cyproheptadine minus placebo). (d) Change in post-pill F-wave persistence values are shown for the group. Individual values for each participant are also shown. For one participant, their cyproheptadine value (~50.1%) is outside the y-axis limits. (e) Individual post-pill F-wave persistence values are shown for the cyproheptadine condition, where cyproheptadine persistence values are presented as a difference from post-pill placebo values. For panels (b) and (d), values are mean ± SD (n = 10), and ‘*’ denotes a significant difference between drug conditions (P < .05).
and a Wilcoxon signed-rank test was used. All statistical
tests were completed using SPSS Statistics (version
27, IBM Corp., USA). A P value of <.05 was considered
statistically significant. All group data are presented in
the text and figures as mean ± SD.

3 | RESULTS

3.1 | Cervicomedullary motor evoked
potentials

Waveform averages of raw biceps CMEPs are shown for a
single participant in Figure 2a. Before pill administration,
the amplitude of baseline CMEPs for the group was
9.7 ± 5.7% of $M_{\text{max}}$ for the placebo session and
8.1 ± 3.4% of $M_{\text{max}}$ for the cyproheptadine session. Biceps
$M_{\text{max}}$ amplitudes are presented in Table 1. Post-pill
CMEP amplitude was not different between the placebo
and cyproheptadine conditions ($t_8 = .22, \ P = .83$
Figure 2b). Figure 2c shows individual change from pla-
 placebo values for post-pill cyproheptadine CMEP
amplitude data.

3.2 | F-waves

Raw ADM F-waves are shown for a single participant in
Figure 3a. Before pill administration, baseline F-wave
amplitude for the group was 2.6 ± .6% of $M_{\text{max}}$ for the
placebo session and 2.5 ± .8% of $M_{\text{max}}$ for the cyprohep-
tadine session. ADM $M_{\text{max}}$ amplitudes are presented in
Table 1. Baseline F-wave persistence was high. For the
group, persistence was 95.9 ± 2.8% for the placebo ses-
sion and 91.6 ± 9.4% for the cyproheptadine session.
Cyproheptadine administration had a strong effect on
both F-wave amplitude and persistence, whereby drug
administration reduced both measures (cyproheptadine

![Figure 4](image-url)

**FIGURE 4** Biceps brachii cervicomedullary motor evoked potential (CMEP) amplitude after a brief contraction of the contralateral
elbow flexors with placebo (PLA) and cyproheptadine (CYP) administration. (a) Raw traces of elbow flexion force generated from the left
limb (upper trace) and biceps EMG recorded from the right limb (lower trace). Participants generated brief elbow flexions of the left limb at
75% of maximal voluntary contraction (MVC), before receiving cervicomedullary and brachial plexus stimulations at rest to evoke muscle
responses in the right biceps. (b) Post-contraction CMEP amplitudes are shown for the group (mean ± SD, $n = 9$). Individual values for each
participant are also shown. CMEP amplitudes were first normalised to the amplitude of the maximal compound muscle action potential
($M_{\text{max}}$, also post-contraction), and then normalised to baseline pre-pill CMEP (% of $M_{\text{max}}$) values. (c) Individual post-contraction CMEP
amplitudes are shown for the cyproheptadine condition, where cyproheptadine amplitudes are presented as a difference from post-
contraction placebo values to show the direction of change for each participant after drug intake (cyproheptadine minus placebo)
amplitude: \(-30.1 \pm 22.3\%\) difference from placebo, cyproheptadine persistence: \(-8.4 \pm 12.2\%\) difference from placebo). The amplitude of post-pill F-waves was significantly different between the placebo and cyproheptadine conditions \((t_8 = 4.26, P = .002, Figure~3b)\). Similarly, post-pill F-wave persistence was different between drug conditions \((Z = -2.50, P = .013, Figure~3d)\). Figure 3c,e shows individual change from placebo values for post-pill cyproheptadine amplitude and persistence data, respectively.

### 3.3 The effects of contralateral contraction on CMEPs

After resting measures had been obtained, participants performed brief MVCs of the left contralateral elbow flexors to determine relevant target contraction intensities for the additional experiment and to establish if the cyproheptadine intervention affected maximal motor output. Indeed, we identified a difference between drug conditions for MVC force \((t_8 = -2.97, P = .016)\), where MVC force for the cyproheptadine condition \((284.6 \pm 74.5\) N) was less than placebo \((303.6 \pm 88.5\) N). Although maximal motor output was affected by drug administration, cyproheptadine did not affect CMEP amplitude measured in the right limb when cervicomedullary stimuli were delivered immediately after submaximal contraction of the left limb (Figure 4). After submaximal elbow flexion of the left contralateral limb, there was no difference between the placebo and cyproheptadine conditions for biceps CMEP amplitude \((t_8 = .084, P = .93)\).

## 4 DISCUSSION

This study examined if 5-HT\(_2\) receptor antagonism affects human motoneuron excitability. Specifically, we assessed the effects of 5-HT\(_2\) antagonism on the synaptic activation of motoneurons via cervicomedullary stimulation, and the antidromic activation and recurrent discharge of motoneurons via peripheral nerve stimulation. Cervicomedullary stimulation delivers a synchronised excitatory volley to motoneurons to evoke a compound muscle action potential but does not cause motoneurons to discharge repetitively and is unlikely to activate PICs. We found that muscle responses from cervicomedullary stimulation were not affected by 5-HT\(_2\) antagonism, but 5-HT\(_2\) antagonism reduced recurrent motoneuron discharge. We also assessed the synaptic activation of motoneurons after a strong contraction of the contralateral limb and found that 5-HT\(_2\) antagonism did not affect muscle responses to cervicomedullary stimulation after remote muscle activity. Yet 5-HT\(_2\) antagonism reduced maximal contraction strength (i.e., when synaptic input generates repetitive firing of motoneurons to activate PICs). Overall, these results provide novel, in vivo, human evidence that 5-HT\(_2\) receptors control the excitability of motoneurons, as evidenced by changes in recurrent discharge after drug administration. In addition, our results indicate that 5-HT\(_2\) receptors modulate responses to synaptic input, but only when synaptic input activates 5-HT\(_2\) receptor mediated dendritic PICs.

### 4.1 5-HT\(_2\) antagonism does not affect CMEPs

We used cervicomedullary stimulation to deliver a brief excitatory volley to motoneurons and recorded the size of the resultant EMG response. Stimulation at the cervicomedullary junction provided a way to assess motoneuron output in response to synaptic input from descending motor pathways (McNeil et al., 2013; Taylor, 2006; Taylor & Gandevia, 2004), where CMEPs have a strong monosynaptic component for the biceps brachii (Petersen et al., 2002). As stimulation intensity was fixed from baseline, cervicomedullary stimulation activated the same number/type of corticospinal axons and caused similar excitation of motoneurons throughout each session. However, even though the synaptic excitation of motoneurons was controlled, 5-HT\(_2\) antagonism had no effect on the output of motoneurons to input provided by a single synchronous volley from descending motor pathways.

Although 5-HT\(_2\) receptors modulate the resting membrane properties of motoneurons to enhance motoneuron excitability (Hsiao et al., 1997), 5-HT\(_2\) receptors exert their most powerful effects on motoneuron excitability by facilitating voltage-gated PICs (Harvey et al., 2006a, 2006b; Murray, Stephens, Ballou, et al., 2011; Perrier & Delgado-Lezama, 2005; Perrier & Hounsgaard, 2003). However, activation of PICs in motoneurons, and especially activation of calcium PICs (Elbasiouny et al., 2006), requires a sustained synaptic excitation. Thus, 5-HT\(_2\) receptor effects on PICs will not be reflected in the amplitude of muscle responses to single-pulse cervicomedullary stimulation. With stimulation of corticospinal axons, motoneurons receive a brief, synchronised input and quickly go from below to above their threshold for discharge. This leaves little time for PICs to activate and influence the intrinsic properties of motoneurons and hence, the amplitude of the CMEP. In decerebrate cat preparations, self-sustained motoneuron firing can be elicited with a high-frequency 1.5-s activation of Ia afferents that brings motoneurons above their
threshold for discharge but provides sufficient time for PICs to activate (Lee & Heckman, 1998). Likewise, in humans, a high-frequency vibration applied for 8 s to the wrist generates a reflexive response that is enhanced by a selective 5-HT reuptake inhibitor (SSRI), an effect that is likely due to a 5-HT facilitation of PICs (Wei et al., 2014). These methods contrast with cervicomedullary stimulation which generates a single EPSP in motoneurons and does not cause repetitive discharge.

The proposition that a sustained depolarizing input is needed to activate PICs, and a reduced PIC facilitation with 5-HT2 antagonism will not reduce motoneuron excitability to a brief synaptic volley, also explains why we identified no drug differences for CMEPs after strong contralateral contraction. In the current study, voluntary contractions of the opposite limb were intended to enhance 5-HT concentration in the spinal cord (Jacobs et al., 2002; Veasey et al., 1995), but PICs in motoneurons projecting to the biceps of the test limb were not active as this muscle was relaxed. We postulate that serotonergic effects after contralateral contraction may be revealed with activation of PICs, for example, if participants voluntarily activate motoneurons projecting to the test biceps. The serotonergic modulation of PICs after remote muscle activity has been indirectly demonstrated in humans. In healthy participants, the variability of muscle contraction force is increased with enhanced 5-HT availability and reduced with 5-HT2 antagonism, and the magnitude of these increases or decreases in force variability is in proportion to the strength of a preceding voluntary contraction from the contralateral limb (Wei et al., 2014).

In this example, changes in force variability were likely mediated by the modulation of PICs by the 5-HT drugs, but PICs were only activated by voluntary contraction. It seems unlikely that the lack of drug effects on post-contraction CMEPs in our study were due to the temporal characteristics of 5-HT reuptake in synapses, as increased motoneuron excitability from 5-HT release has been detected up until 8.5 s after stimulation of the raphe nuclei in turtle preparations (Perrier & Delgado-Lezama, 2005). In our protocol, CMEPs were obtained ~1 s after contraction, which means that the effects of 5-HT release were still present when measurements of motoneuron excitability were made.

4.2 F-waves are reduced with 5-HT2 antagonism

Another way to assess motoneuron excitability is to measure the amplitude and persistence of recurrent motoneuron discharge, or F-waves when measured with surface EMG, after supramaximal stimulation of a motor nerve (Fisher, 1992; McNeil et al., 2013; Mesrati & Vecchierini, 2004). F-waves reflect the antidromic activation and subsequent backfiring of motoneurons. Hence, the generation of F-waves does not require synaptic input. We found that 5-HT2 antagonism reduced the amplitude and persistence of recurrent motoneuron discharge, which demonstrates reductions in motoneuron excitability with reduced 5-HT2 receptor activity.

Considering that recurrent discharge was generated in motoneurons that are otherwise below their threshold for discharge (prior to stimulation), drug reductions in motoneuron excitability can be attributed to effects on resting membrane properties and not PICs. In guinea pig motoneurons, 5-HT2 receptor activation increases excitability below recruitment threshold by inhibiting leak potassium channels and facilitating a hyperpolarization activated inward current (Hsiao et al., 1997). In our study, 5-HT2 antagonism could have combatted these facilitatory effects to reduce motoneuron excitability and reduce F-waves. However, this does not explain why muscle responses to antidromic but not synaptic activation of motoneurons were affected by drug, as overall changes in intrinsic properties of motoneurons affect both measures. One possibility is that drug administration affected the motoneuron soma to reduce the time between antidromic and orthodromic spikes at the axon initial segment. Although speculative, 5-HT2 antagonism with cyproheptadine could have reduced the amplitude of the persistent sodium current, which is faster to activate than persistent calcium currents (Heckman, Johnson, et al., 2008), to reduce the duration of somatic depolarization. In turn, a shorter duration somatic depolarization would increase the likelihood of an orthodromic spike reaching a refractory axon initial segment. Although there is limited evidence for this idea, 5-HT2 receptors facilitate sodium PICs in rat motoneurons (Harvey et al., 2006a, 2006b).

Another possibility is that cyproheptadine differently affected different motoneuron types. F-waves represent the recurrent discharge of higher threshold motoneurons, as the simultaneous stimulation of Ia afferents initiates orthodromic spikes in lower threshold motoneurons that collide with the antidromic spikes that generate recurrent discharge (Espiritu et al., 2003). By contrast, stimulation of corticospinal axons recruits motoneurons in an orderly fashion from lower to higher threshold (Bawa & Lemon, 1993). In this regard, as we set the intensity of cervicomedullary stimulation to elicit small CMEPs (~10% of Mmax), CMEPs in this study reflect the excitability of lower threshold motoneurons. As F-waves but not CMEPs were reduced with drug, this indicates that 5-HT2 antagonism may have affected higher threshold motoneurons more than lower threshold.
4.3  5-HT2 antagonism reduces motor output

Although there is a low level of tonic 5-HT release to motoneurons in the waking state, stimulation assessed motoneuron excitability under conditions with no ionotropic drive to activate motoneurons. However, voluntary motor activity causes greater 5-HT release to motoneurons (Jacobs et al., 2002; Veasey et al., 1995), and neuromodulatory effects at motoneurons are strongest with high-intensity motor activities involving strong serotonergic drive and sustained ionotropic input to activate PICs (Heckman et al., 2003, 2009). Our maximal contraction findings are consistent with this, as 5-HT2 antagonism reduced the force generated during maximal contractions. This is not an accidental finding, as enhanced 5-HT availability increases maximal strength and/or voluntary activation (Kavanagh et al., 2019; Thorstensen et al., 2020), and maximal contractions were also negatively affected with 5-HT2 antagonism in a previous study (Thorstensen et al., 2021). Considering that maximal contractions are generated via sustained input to motoneurons, we suggest that 5-HT2 antagonism reduced the amplitude of PICs to negatively affect the ability of participants to voluntarily activate motoneurons leading to reductions in muscle force.

4.4  Considerations

Both stimulation techniques assessed a small proportion of the motoneuron pool and thus might not reflect overall changes in excitability, and cyproheptadine may have affected biceps and ADM pools differently. Also, increases or decreases in F-wave amplitude or persistence do not always represent corresponding increases or decreases in motoneuron excitability (Balbi, 2016; Balbi et al., 2014; Lin & Floeter, 2004). As afferent fibres are also activated with supramaximal stimulation of peripheral nerves and 5-HT modulates afferent input to motoneurons (D’Amico, Li, et al., 2013; Murray, Stephens, Rank, et al., 2011), 5-HT effects on F-waves could potentially be a consequence of pre-synaptic mechanisms. However, the serotonergic control of afferent input to human motoneurons is via 5-HT1B/D receptors (D’Amico, Li, et al., 2013), and cyproheptadine has weak effects at these receptors.

5  CONCLUSION

This study provides novel in vivo evidence that 5-HT2 receptors play a role in controlling the excitability of human motoneurons, as evidenced by reductions in F-waves with 5-HT2 antagonism. Considering that assessments of motoneuron excitability were obtained when muscles were inactive and thus, motoneurons were otherwise below their threshold for discharge, the reduced recurrent discharge of motoneurons with 5-HT2 antagonism suggests that 5-HT modulates the resting membrane properties of the axon initial segment or soma to promote motoneuronal excitability. In addition, as 5-HT2 antagonism had no effect on motoneuron excitability to brief synaptic input, but affected maximal contractions requiring sustained synaptic input, it is likely that the 5-HT-mediated amplification of synaptic input at motoneurons is strong only when dendritic PICs are activated.

ACKNOWLEDGEMENTS

There are no acknowledgements to declare, and no funding was received for this work. Open access publishing facilitated by Griffith University, as part of the Wiley - Griffith University agreement via the Council of Australian University Librarians. [Correction added on 21 May 2022, after first online publication: CAUL funding statement has been added.]

CONFLICT OF INTEREST

None to declare.

AUTHOR CONTRIBUTIONS

JRT, JLT and JJK contributed to the conception and the design of this study. JRT, JLT and JJK contributed to the interpretation, drafting and final approval of the manuscript. Data collection and analysis were performed by JRT at Griffith University.

PEER REVIEW

The peer review history for this article is available at https://publons.com/publon/10.1111/ejn.15672.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Jacob R. Thorstensen  https://orcid.org/0000-0002-6821-1547
Janet L. Taylor  https://orcid.org/0000-0001-8976-5162
Justin J. Kavanagh  https://orcid.org/0000-0002-1046-260X

REFERENCES

Alvarez, F. J., Pearson, J. C., Harrington, D., Dewey, D., Torbeck, L., & Fyffe, R. E. (1998). Distribution of 5-hydroxytryptamine-immunoreactive boutons on alpha-motoneurons in the lumbar spinal cord of adult cats. The Journal of Comparative Neurology,
Murray, K. C., Nakae, A., Stephens, M. J., Rank, M., D’Amico, J., Harvey, P. J., Li, X., Harris, R. L., Ballou, E. W., Anelli, R., Heckman, C. J., Mashimo, T., Vavrek, R., Sanelli, L., Gorassini, M. A., Bennett, D. J., & Fouad, K. (2010). Recovery of motoneuron and locomotor function after spinal cord injury depends on constitutive activity in 5-HT2C receptors. *Nature Medicine, 16,* 694–700. https://doi.org/10.1038/nm.2160

Murray, K. C., Stephens, M. J., Ballou, E. W., Heckman, C. J., & Bennett, D. J. (2011). Motoneuron excitability and muscle spasms are regulated by 5-HT2B and 5-HT2C receptor activity. *Journal of Neurophysiology, 105,* 731–748. https://doi.org/10.1152/jn.00774.2010

Murray, K. C., Stephens, M. J., Rank, M., D’Amico, J., Gorassini, M. A., & Bennett, D. J. (2011). Polysynaptic excitatory postsynaptic potentials that trigger spasms after spinal cord injury in rats are inhibited by 5-HT1B and 5-HT1F receptors. *Journal of Neurophysiology, 106,* 925–943. https://doi.org/10.1152/jn.00110.2010

Perrier, J. F., & Cotel, F. (2015). Serotonergic modulation of spinal motor control. *Current Opinion in Neurobiology, 33,* 1–7. https://doi.org/10.1016/j.conb.2014.12.008

Perrier, J. F., & Delgado-Lezama, R. (2005). Synaptic release of serotonin induced by stimulation of the raphe nucleus promotes plateau potentials in spinal motoneurons of the adult turtle. *The Journal of Neuroscience, 25*(35), 7993–7999. https://doi.org/10.1523/JNEUROSCI.1523-05.2005

Perrier, J. F., & Hounsgaard, J. (2003). 5-HT2 receptors promote plateau potentials in turtle spinal motoneurons by facilitating an L-type calcium current. *Journal of Neurophysiology, 89,* 954–959. https://doi.org/10.1152/jn.00753.2002

Perrier, J. F., Rasmussen, H. B., Christensen, R. K., & Petersen, A. V. (2013). Modulation of the intrinsic properties of motoneurons by serotonin. *Current Pharmaceutical Design, 19*(24), 4371–4384. https://doi.org/10.2174/13816128113199990341

Petersen, N. T., Taylor, J. L., & Gandevia, S. C. (2002). The effect of electrical stimulation of the corticospinal tract on motor units of the human biceps brachii. *The Journal of Physiology, 544*(1), 277–284. https://doi.org/10.1113/physiol.2002.024539

Pilowsky, P. M., de Castro, D., Llewellyn-Smith, I., Lipski, J., & Voss, M. D. (1990). Serotonin immunoreactive boutons make synapses with feline phrenic motoneurons. *The Journal of Neuroscience, 10*(4), 1091–1098. https://doi.org/10.1523/JNEUROSCI.10-04-1091.1990

Rekling, J. C., Funk, G. D., Bayliss, D. A., Dong, X. W., & Feldman, J. L. (2000). Synaptic control of motoneuronal excitability. *Physiological Reviews, 80,* 767–852. https://doi.org/10.1152/physrev.2000.80.2.767

Ridet, J. L., Tamir, H., & Privat, A. (1994). Direct immunocyto-chemical localization of 5-hydroxytryptamine receptors in the adult rat spinal cord: A light and electron microscopic study using an anti-idiotypic antiserum. *Journal of Neuroscience Research, 38,* 109–121. https://doi.org/10.1002/jnr.490380114

Seo, N. J., Fischer, H. W., Bogey, R. A., Rymer, W. Z., & Kamper, D. G. (2011). Effect of a serotonin antagonist on delay in grip muscle relaxation for persons with chronic hemiparetic stroke. *Clinical Neurophysiology, 122*(4), 796–802. https://doi.org/10.1016/j.clinph.2010.10.035

Taylor, J. L. (2006). Stimulation at the cervico-medullary junction in human subjects. *Journal of Electromyography and Kinesiology, 16*(3), 215–223. https://doi.org/10.1016/j.jelekin.2005.07.001

Taylor, J. L., & Gandevia, S. C. (2004). Noninvasive stimulation of the human corticospinal tract. *Journal of Applied Physiology (1985), 96*(4), 1496–1503. https://doi.org/10.1152/japplphysiol.01116.2003

Taylor, J. L., & Martin, P. G. (2009). Voluntary motor output is altered by spike-timing-dependent changes in the human corticospinal pathway. *The Journal of Neuroscience, 29*(37), 11708–11716. https://doi.org/10.1523/JNEUROSCI.2217-09.2009

Thorstensen, J. R., Taylor, J. L., & Kavanagh, J. J. (2021). Human corticospinal-motoneuronal output is reduced with 5-HT2 receptor antagonism. *Journal of Neurophysiology, 125*(4), 1279–1288. https://doi.org/10.1152/jn.00698.2020

Thorstensen, J. R., Taylor, J. L., Tucker, M. G., & Kavanagh, J. J. (2020). Enhanced serotonin availability amplifies fatigue perception and modulates the TMS-induced silent period during sustained low-intensity elbow flexions. *The Journal of Physiology, 598*(13), 2685–2701. https://doi.org/10.1113/JP279347

Ugawa, Y., Rothwell, J. C., Day, B. L., Thompson, P. D., & Marsden, C. D. (1991). Percutaneous electrical stimulation of corticospinal pathways at the level of the pyramidal decussation in humans. *Annals of Neurology, 29,* 418–427. https://doi.org/10.1002/ana.410290413

Veasey, S. C., Fornal, C. A., Metzler, C. W., & Jacobs, B. L. (1995). Response of serotonergic caudal raphe neurons in relation to specific motor activities in freely moving cats. *The Journal of Neuroscience, 15*(7), 5346–5359. https://doi.org/10.1523/JNEUROSCI.15-07-05346.1995

Wei, K., Glaser, J. I., Deng, L., Thompson, C. K., Stevenson, I. H., Wang, Q., Hornby, T. G., Heckman, C. J., & Kording, K. P. (2014). Serotonin affects movement gain control in the spinal cord. *The Journal of Neuroscience, 34*(38), 12690–12700. https://doi.org/10.1523/JNEUROSCI.1855-14.2014

Zhang, M. (2015). Aromatic L-amino acid decarboxylase cells in the spinal cord: A potential origin of monoamines. *Current Opinion in Neurobiology, 36*(4), 5374–5379. https://doi.org/10.1016/j.conb.2015.01.005

How to cite this article: Thorstensen, J. R., Taylor, J. L., & Kavanagh, J. J. (2022). 5-HT2 receptor antagonism reduces human motoneuron output to antidromic activation but not to stimulation of corticospinal axons. *European Journal of Neuroscience, 56*(1), 3674–3686. https://doi.org/10.1111/ejnp.15672